Parallel Advisors’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $28M | Buy |
30,405
+439
| +1% | +$445K | 0.5% | 39 |
|
|
2025
Q4 | $32.2M | Buy |
29,966
+749
| +3% | +$716K | 0.59% | 27 |
|
|
2025
Q3 | $22.3M | Buy |
29,217
+735
| +3% | +$547K | 0.41% | 40 |
|
|
2025
Q2 | $22.2M | Sell |
28,482
-491
| -2% | -$382K | 0.44% | 38 |
|
|
2025
Q1 | $23.9M | Buy |
28,973
+2,696
| +10% | +$2.24M | 0.54% | 26 |
|
|
2024
Q4 | $20.3M | Buy |
26,277
+2,628
| +11% | +$2.18M | 0.46% | 38 |
|
|
2024
Q3 | $21M | Sell |
23,649
-624
| -3% | -$561K | 0.49% | 31 |
|
|
2024
Q2 | $22M | Buy |
24,273
+527
| +2% | +$422K | 0.56% | 25 |
|
|
2024
Q1 | $18.5M | Buy |
23,746
+580
| +3% | +$413K | 0.5% | 32 |
|
|
2023
Q4 | $13.5M | Buy |
23,166
+106
| +0.5% | +$61.9K | 0.4% | 46 |
|
|
2023
Q3 | $12.4M | Buy |
23,060
+333
| +1% | +$172K | 0.41% | 47 |
|
|
2023
Q2 | $10.7M | Buy |
22,727
+714
| +3% | +$299K | 0.34% | 63 |
|
|
2023
Q1 | $7.56M | Buy |
22,013
+1,644
| +8% | +$554K | 0.25% | 82 |
|
|
2022
Q4 | $7.45M | Buy |
20,369
+559
| +3% | +$198K | 0.32% | 49 |
|
|
2022
Q3 | $6.41M | Buy |
19,810
+426
| +2% | +$135K | 0.29% | 59 |
|
|
2022
Q2 | $6.29M | Buy |
19,384
+206
| +1% | +$61.8K | 0.29% | 58 |
|
|
2022
Q1 | $5.56M | Buy |
19,178
+3,556
| +23% | +$915K | 0.22% | 74 |
|
|
2021
Q4 | $4.32M | Buy |
15,622
+653
| +4% | +$166K | 0.16% | 101 |
|
|
2021
Q3 | $3.46M | Sell |
14,969
-1,930
| -11% | -$476K | 0.14% | 109 |
|
|
2021
Q2 | $3.88M | Buy |
16,899
+539
| +3% | +$108K | 0.16% | 96 |
|
|
2021
Q1 | $3.06M | Buy |
16,360
+3,056
| +23% | +$598K | 0.14% | 104 |
|
|
2020
Q4 | $2.25M | Sell |
13,304
-2,202
| -14% | -$329K | 0.12% | 131 |
|
|
2020
Q3 | $2.29M | Buy |
15,506
+109
| +0.7% | +$16.9K | 0.14% | 113 |
|
|
2020
Q2 | $2.53M | Sell |
15,397
-2,410
| -14% | -$370K | 0.16% | 95 |
|
|
2020
Q1 | $2.47M | Sell |
17,807
-3,949
| -18% | -$543K | 0.2% | 82 |
|
|
2019
Q4 | $2.86M | Buy |
21,756
+1,576
| +8% | +$183K | 0.21% | 83 |
|
|
2019
Q3 | $2.26M | Sell |
20,180
-574
| -3% | -$63.9K | 0.19% | 90 |
|
|
2019
Q2 | $2.3M | Sell |
20,754
-1,445
| -7% | -$170K | 0.22% | 79 |
|
|
2019
Q1 | $2.88M | Sell |
22,199
-1,563
| -7% | -$190K | 0.32% | 58 |
|
|
2018
Q4 | $2.75M | Sell |
23,762
-248
| -1% | -$27.7K | 0.38% | 49 |
|
|
2018
Q3 | $2.58M | Buy |
24,010
+3,384
| +16% | +$338K | 0.32% | 55 |
|
|
2018
Q2 | $1.76M | Sell |
20,626
-32
| -0.2% | -$2.63K | 0.25% | 70 |
|
|
2018
Q1 | $1.6M | Buy |
20,658
+85
| +0.4% | +$6.84K | 0.25% | 76 |
|
|
2017
Q4 | $1.74M | Sell |
20,573
-38
| -0.2% | -$3.23K | 0.28% | 63 |
|
|
2017
Q3 | $1.71M | Sell |
20,611
-277
| -1% | -$22.7K | 0.29% | 63 |
|
|
2017
Q2 | $1.73M | Buy |
20,888
+70
| +0.3% | +$5.71K | 0.33% | 61 |
|
|
2017
Q1 | $1.69M | Buy |
20,818
+2,004
| +11% | +$161K | 0.34% | 62 |
|
|
2016
Q4 | $1.38M | Buy |
+18,814
| New | +$1.4M | 0.33% | 62 |
|
Other funds holding LLY
VCM
VPM
Parallel Advisors's LLY Position: Q1 2026 in Review
Parallel Advisors increased its Eli Lilly (LLY) stake by 1.5% in Q1 2026, buying an estimated $445K and bringing the position to 30,405 shares worth $28M. The position accounts for 0.5% of the portfolio, ranked #39.
Parallel Advisors first reported a position in LLY in Q4 2016 and has held it in 38 quarters since. The position peaked at $32.2M in Q4 2025. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.
- Parallel Advisors held 30,405 shares of Eli Lilly worth $28M as of Q1 2026.
- Parallel Advisors bought 439 Eli Lilly shares in Q1 2026, an estimated $445K.
- Eli Lilly made up 0.5% of Parallel Advisors's portfolio in Q1 2026, its #39 holding.
- Parallel Advisors first reported a position in Eli Lilly in Q4 2016 and has held it in 38 quarters since.
- Parallel Advisors's Eli Lilly position peaked at $32.2M in Q4 2025.
- 4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.
Based on Parallel Advisors's 13F filing for Q1 2026, filed 7 May 2026.